Women's Hair Loss: Causes, Treatments, and What Actually Works

How Common Is Hair Loss in Women?

About one in three women will notice clinically significant hair thinning during her lifetime, and prevalence rises sharply after menopause. A population-based study published in the Journal of the American Academy of Dermatology found that FPHL affected 19% of women in their 30s, rising to 37.8% in women aged 70 and older [1]. Those numbers likely undercount reality because many women never seek evaluation.

Unlike male pattern baldness, which produces a receding hairline and vertex thinning, women typically lose density across the crown and part line while the frontal hairline stays intact. The Ludwig classification system grades this diffuse thinning from grade I (mild widening of the central part) through grade III (near-total loss over the crown) [2]. Recognizing the pattern matters because it directs the workup. A dermatologist who sees diffuse shedding without miniaturization will suspect telogen effluvium or a systemic cause rather than FPHL.

Hair cycling also differs between the sexes. Women maintain a longer anagen (growth) phase, which is why baseline hair length tends to be greater. But when disrupted by androgens, nutritional deficits, or autoimmune inflammation, the anagen phase shortens and the telogen (resting) phase lengthens, producing visible thinning over months to years [3].

What Causes Female Pattern Hair Loss?

FPHL is driven by a combination of genetic susceptibility and androgen activity at the follicular level, though the hormonal picture in women is more nuanced than the straightforward DHT story in men. Women with FPHL frequently have normal circulating androgen levels, suggesting that local enzyme activity (particularly 5-alpha reductase and aromatase expression in scalp tissue) plays a larger role than serum testosterone [4].

The Endocrine Society's 2019 clinical practice guideline on hyperandrogenism notes that "androgen excess should be excluded but is not required for the diagnosis of female pattern hair loss" [5]. This means a woman can have completely normal labs and still carry a confirmed FPHL diagnosis based on dermoscopy findings such as follicular miniaturization, variable hair shaft diameter, and perifollicular brown halos.

Genetics load the gun. A family history of thinning on either the maternal or paternal side increases risk significantly. Twin studies suggest heritability of androgenetic alopecia exceeds 80% [6]. But environment, hormones, and nutrition pull the trigger.

Telogen Effluvium: The Other Major Cause

Telogen effluvium (TE) accounts for a large share of acute hair shedding complaints in women. It occurs when a physiologic stressor pushes a disproportionate number of follicles from anagen into telogen simultaneously. Two to four months later, those hairs fall out in alarming quantities.

Common triggers include [7]:

• Childbirth (postpartum TE affects an estimated 40-50% of new mothers)
• Crash dieting or rapid weight loss, including after GLP-1 agonist initiation
• Major surgery or hospitalization
• High fever, including post-COVID shedding
• Thyroid dysfunction (both hypo- and hyperthyroidism)
• Iron deficiency, even without frank anemia
• Discontinuation of oral contraceptives

The hallmark of TE is diffuse shedding without miniaturization. A gentle hair pull test yields more than six telogen hairs. The reassuring news: classic acute TE is self-limiting. Once the trigger resolves, regrowth begins within 3 to 6 months and full density typically returns by 12 to 18 months [7]. Chronic TE, defined as shedding persisting beyond 6 months, requires a more thorough metabolic and hormonal workup.

The Lab Workup Every Woman Should Request

Before starting any treatment, a directed laboratory evaluation helps identify reversible contributors. The American Academy of Dermatology recommends the following baseline panel for women presenting with hair loss [8]:

Thyroid function. TSH and free T4. Subclinical hypothyroidism (TSH 4.5-10 mIU/L) can produce diffuse thinning even before other symptoms appear.

Iron stores. Serum ferritin is the most useful single marker. A 2017 meta-analysis in Dermatology and Therapy found that women with hair loss had significantly lower ferritin than controls, and many dermatologists target ferritin above 40 ng/mL (some aim for 70 ng/mL) for optimal hair cycling [9]. Checking ferritin alongside a CBC helps distinguish iron deficiency from iron deficiency anemia.

Androgens. Total testosterone, free testosterone, and DHEA-S. An elevated free testosterone or DHEA-S may point toward PCOS or an adrenal source and changes the treatment approach.

Vitamin D. 25-hydroxyvitamin D. Observational studies have linked levels below 30 ng/mL with increased risk of both TE and FPHL, though the causal relationship remains debated [10].

Additional tests when indicated. ANA (if alopecia areata is suspected), zinc, B12, prolactin, and a comprehensive metabolic panel if systemic disease is on the differential.

A normal workup does not mean "nothing is wrong." It means FPHL driven by local follicular androgen sensitivity is the most likely diagnosis.

FDA-Approved Treatment: Topical Minoxidil

Topical minoxidil remains the first-line, FDA-approved treatment for FPHL. The 5% foam formulation, initially approved only for men, received FDA clearance for women in 2014 after the key Olsen et al. trial demonstrated superior regrowth compared to 2% solution [11].

In a 48-week randomized controlled trial (N=381), women using 5% minoxidil foam once daily showed a mean increase of 18.6 non-vellus hairs per cm² in the target area versus 12.7 for 2% solution [11]. The 5% foam also produced less scalp irritation due to the absence of propylene glycol.

Application protocol: one capful (approximately 1 mL) applied directly to the dry scalp along the part line once daily. It must contact the scalp, not the hair shafts. Initial shedding during weeks 2 through 8 is common and actually signals therapeutic response as miniaturized telogen hairs are pushed out by new anagen hairs.

The drug requires continuous use. A discontinuation study showed that gains were lost within 4 to 6 months of stopping [12]. This is not a cure. It is ongoing maintenance.

Off-Label Treatments With Strong Evidence

Spironolactone

Spironolactone, an aldosterone antagonist with potent anti-androgen properties, is the most widely prescribed off-label oral therapy for FPHL in women. It blocks androgen receptors in the hair follicle and reduces adrenal androgen production.

A retrospective study of 166 women treated with spironolactone 200 mg daily published in the British Journal of Dermatology found that 74% reported stabilization or improvement at 12 months [13]. The Endocrine Society and multiple international dermatology guidelines support its use in women with FPHL, though it is absolutely contraindicated in pregnancy due to the risk of feminization of a male fetus [5].

Common side effects include orthostatic lightheadedness, breast tenderness, and menstrual irregularity. Potassium monitoring is recommended at baseline and after dose titration, though the risk of clinically significant hyperkalemia in healthy young women is low. "In my experience, the biggest barrier to spironolactone is not side effects but patience," notes Dr. Antonella Tosti, a professor of dermatology at the University of Miami. "Women need to commit to at least 12 months before assessing efficacy."

Low-Dose Oral Minoxidil

Oral minoxidil at doses of 0.25 mg to 2.5 mg daily has emerged as a game-shifting option for women who find topical application impractical or who experience scalp irritation. A systematic review in the Journal of the American Academy of Dermatology (2020) covering 17 studies and 634 patients found that low-dose oral minoxidil produced clinically meaningful hair regrowth in the majority of women with FPHL, with hypertrichosis (unwanted facial/body hair) as the most common side effect at doses above 1.25 mg [14].

Cardiovascular screening is appropriate before prescribing. Blood pressure should be checked at baseline and periodically, though at these doses, hemodynamic effects are minimal in normotensive patients. A 2022 prospective trial of oral minoxidil 1.25 mg daily in 30 women with FPHL found no significant changes in heart rate or blood pressure over 24 weeks, with 77% of participants showing photographic improvement [15].

Platelet-Rich Plasma (PRP)

PRP involves drawing the patient's blood, concentrating the platelet fraction, and injecting it into the scalp. A meta-analysis published in Dermatologic Surgery (2019) pooled 11 RCTs and found that PRP-treated areas showed significantly greater hair density and thickness compared to placebo-injected areas [16]. Protocols vary widely. Most studies used 3 to 4 monthly sessions followed by maintenance every 3 to 6 months.

PRP works best as an adjunct, not a standalone. Combining PRP with topical minoxidil produced additive results in a head-to-head comparison published in the Journal of Cosmetic Dermatology [17].

Hormonal Hair Loss: Menopause, PCOS, and Postpartum

Menopause

The perimenopausal transition accelerates FPHL due to declining estrogen and a relative increase in androgen influence. Estrogen supports the anagen phase directly, and its loss shortens the growth cycle. The North American Menopause Society states that "menopause-related hair changes are among the most distressing symptoms reported by women, yet remain undertreated" [18].

Hormone replacement therapy (HRT) with systemic estradiol may slow menopause-related thinning, particularly when combined with a non-androgenic progestogen like micronized progesterone or drospirenone. Medroxyprogesterone acetate and norethindrone, which have androgenic activity, can worsen hair loss and should be avoided in women with FPHL [18].

PCOS

Polycystic ovary syndrome affects up to 15% of reproductive-age women, and hair loss is among the most psychologically distressing symptoms [19]. The androgen excess that defines PCOS directly miniaturizes susceptible follicles. Combined oral contraceptives containing anti-androgenic progestins (drospirenone, cyproterone acetate outside the U.S.) paired with spironolactone form the standard approach. Metformin alone has not shown consistent benefit for hair outcomes in PCOS trials, though it may contribute when insulin resistance is a dominant feature [19].

Postpartum Shedding

Postpartum TE results from the synchronized shift of follicles that remained in anagen during pregnancy's high-estrogen state. The shedding is dramatic but temporary. It does not require pharmacologic treatment in most cases. Ensuring adequate iron stores, continuing prenatal vitamins, and reassurance that regrowth will occur by 6 to 12 months postpartum is the standard recommendation [7].

GLP-1 Agonists and Hair Loss: What the Data Show

Reports of hair shedding during semaglutide and tirzepatide treatment have gained attention. In the STEP-1 trial (N=1,961), alopecia was reported by 3.0% of participants receiving semaglutide 2.4 mg versus 1.0% on placebo [20]. The mechanism is almost certainly caloric-deficit-induced TE rather than a direct drug effect. Rapid weight loss from any cause, whether surgical or pharmacologic, triggers telogen conversion.

The SURMOUNT-1 trial of tirzepatide (N=2,539) reported alopecia in 4.9 to 5.7% of active treatment groups compared to 0.9% in the placebo arm [21]. Higher rates correlated with greater weight loss magnitude. Women starting a GLP-1 agonist should be counseled proactively: the shedding typically peaks at months 3 to 6 and self-resolves as weight stabilizes. Adequate protein intake (1.0 to 1.2 g/kg/day) and iron sufficiency may attenuate the severity.

When to See a Specialist

Primary care can manage straightforward TE and initiate minoxidil for mild FPHL. Referral to a dermatologist with hair-loss expertise is appropriate when:

• The pattern is atypical (patchy, scarring, or rapidly progressive)
• Ludwig grade II or III is present on examination
• Labs suggest an endocrine disorder requiring subspecialty input
• The patient has failed 12 months of first-line therapy
• Scalp biopsy is needed to distinguish FPHL from chronic TE or early cicatricial alopecia

A trichoscopy (dermoscopic examination of the scalp) can be performed in-office and often provides enough diagnostic information to avoid biopsy. Features like hair diameter diversity greater than 20%, yellow dots, and peripilar signs are specific for FPHL [22].

Building a Treatment Timeline

Expect no visible change before month 3. Standardized global photography at baseline, 6 months, and 12 months is the most objective way to track progress. Minoxidil and spironolactone both require 6 to 12 months to reach peak effect. Women who add PRP typically see incremental gains at 3 to 4 months after the loading series. A ferritin level rechecked at 3 months after starting supplementation confirms whether iron repletion is on track. The target: ferritin above 50 ng/mL with stable hemoglobin.